In subgroup analyses , all cause mortality was significantly lower in trials with vitamin D3 supplementation than in trials with vitamin D2 supplementation ( P for interaction=0.04 ) ; neither vitamin D3 nor vitamin D2 was associated with a statistically significant reduction in all cause mortality .
CONCLUSIONS Vitamin D supplementation alone was not associated with  all cause mortality in adults compared with placebo or no treatment .
Vitamin D supplementation reduced the risk of cancer death by 16 % .
Additional large clinical studies are needed to determine whether vitamin D3 supplementation is associated with lower all cause mortality .
OBJECTIVE To investigate whether vitamin D supplementation is associated with lower mortality in adults .
Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients.
OBJECTIVE This study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D₃ 1000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D insufficiency in osteoporosis . DESIGN A 6-month international , r and omized , double-blind , parallel-group , phase 3 study . METHODS A total of 518 men and postmenopausal women aged ≥50 years with primary osteoporosis ( T-score ≤-2.5 s.d . ) and serum 25-hydroxyvitamin D ( 25(OH)D ) > 22.5 nmol/l were included . Patients were allocated to strontium ranelate 2 g/vitamin D₃ 1000 IU daily ( n=413 ) or strontium ranelate 2 g daily ( n=105 ) . The participants received calcium 1 g daily . The primary endpoint was serum 25(OH)D at last post-baseline evaluation during 3 months . RESULTS Both groups were comparable at baseline . Mean baseline of 25(OH)D was 44.1 ± 14.6 nmol/l . After 3 months , the percentage of patients with 25(OH)D ≥50 nmol/l was higher with strontium ranelate/vitamin D₃ vs strontium ranelate ( 84 vs 44 % , P<0.001 ; adjusted between-group odds ratio=6.7 ; 95 % CI , 4.2 - 10.9 ) . The efficacy of the fixed-dose combination on 25(OH)D was maintained at 6 months ( 86 vs 40 % , P<0.001 ) . Mean 25(OH)D was 65.1 and 49.5 nmol/l , respectively , after 3 months and 66.9 and 45.4 nmol/l after 6 months . Physical performance improved in both groups . Falls were 17 and 20 % in the strontium ranelate/vitamin D₃ and strontium ranelate groups respectively . Parathyroid hormone levels were inversely correlated with 25(OH)D. No clinical ly relevant differences in safety were observed . CONCLUSIONS This study confirms the efficacy and safety of fixed-dose combination of strontium ranelate 2 g/vitamin D₃ 1000 IU for correction of vitamin D insufficiency in osteoporotic patients
In subgroup analyses , all cause mortality was significantly lower in trials with vitamin D3 supplementation than in trials with vitamin D2 supplementation ( P for interaction=0.04 ) ; neither vitamin D3 nor vitamin D2 was associated with a statistically significant reduction in all cause mortality .
CONCLUSIONS Vitamin D supplementation alone was not associated with  all cause mortality in adults compared with placebo or no treatment .
Vitamin D supplementation reduced the risk of cancer death by 16 % .
Additional large clinical studies are needed to determine whether vitamin D3 supplementation is associated with lower all cause mortality .
OBJECTIVE To investigate whether vitamin D supplementation is associated with lower mortality in adults .